1-Methyl tryptophan, an indoleamine 2,3-dioxygenase inhibitor, attenuates cardiac and hepatic dysfunction in rats with biliary cirrhosis

Shayesteh, Sevda; Guillemin, Gilles J.; Rashidian, Amir; Faghir‐Ghanesefat, Hedyeh; Mani, AR; Tavangar, Seyed Mohammad; Dehpour, Ahmad Reza

doi:10.1016/j.ejphar.2021.174309

Cited by 6 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…235 Consistently, treatment with 1-MT alleviates liver inflammation and fibrosis in the rat model of biliary cirrhosis. 113 Treatment with 1-MT also improved cardiac chronotropic response to epinephrine in the rat model of cirrhotic cardiomyopathy. 113 Regarding the involvement of kynurenine metabolites in cardiac remodeling and hepatic fibrosis and the mutual interaction between cirrhosis and cardiac dysfunction, modulation of kynurenine pathway may be a suitable therapeutic approach to preserve the function of the heart and liver.…”

Section: Kynurenine Links Cirrhosis To Cardiovascular Diseasesmentioning

confidence: 91%

Section: Kynurenine Links Cardiovascular Diseases With Other Diseasesmentioning

confidence: 91%

“…113 Treatment with 1-MT also improved cardiac chronotropic response to epinephrine in the rat model of cirrhotic cardiomyopathy. 113…”

Section: Kynurenine Links Cardiovascular Diseases With Other Diseasesmentioning

confidence: 91%

“…Bądzyńska et al 112 indicated that kynurenic acid 25 mg/kg/day for 3 weeks could selectively decrease heart rate in rats without a significant impact on mean arterial pressure. Shayesteh et al 113 revealed that 1-MT, in a dose-dependent manner, ameliorates cirrhosis-induced chronotropic dysfunction and improves heart response to epinephrine. Metabolomics analysis of 502 patients showed that quinolinic acid was positively correlated with atrial fibrillation (95% CI, OR 1.15 [1.01-1.32]).…”

Section: Kynurenine Pathway Heart Rate and Arrhythmiasmentioning

confidence: 99%

See 3 more Smart Citations

The Footprint of Kynurenine Pathway in Cardiovascular Diseases

Ala

Eftekhar

2022

Int J�Tryptophan�Res

View full text Add to dashboard Cite

Kynurenine pathway is the main route of tryptophan metabolism and produces several metabolites with various biologic properties. It has been uncovered that several cardiovascular diseases are associated with the overactivation of kynurenine pathway and kynurenine and its metabolites have diagnostic and prognostic value in cardiovascular diseases. Furthermore, it was found that several kynurenine metabolites can differently affect cardiovascular health. For instance, preclinical studies have shown that kynurenine, xanthurenic acid and cis-WOOH decrease blood pressure; kynurenine and 3-hydroxyanthranilic acid prevent atherosclerosis; kynurenic acid supplementation and kynurenine 3-monooxygenase (KMO) inhibition improve the outcome of stroke. Indoleamine 2,3-dioxygenase (IDO) overactivity and increased kynurenine levels improve cardiac and vascular transplantation outcomes, whereas exacerbating the outcome of myocardial ischemia, post-ischemic myocardial remodeling, and abdominal aorta aneurysm. IDO inhibition and KMO inhibition are also protective against viral myocarditis. In addition, dysregulation of kynurenine pathway is observed in several conditions such as senescence, depression, diabetes, chronic kidney disease (CKD), cirrhosis, and cancer closely connected to cardiovascular dysfunction. It is worth defining the exact effect of each metabolite of kynurenine pathway on cardiovascular health. This narrative review is the first review that separately discusses the involvement of kynurenine pathway in different cardiovascular diseases and dissects the underlying molecular mechanisms.

show abstract

Section: Kynurenine Links Cirrhosis To Cardiovascular Diseasesmentioning

confidence: 91%